The results of the seventh batch of national drug centralized purchase and selection were released. The average price of drugs dropped by 48%. The mechanism of standby supply enterprises was introduced to implement the "inter product fuse" - the "slimming" of drug prices. What benefits did it bring to patients? Reading tips: the results of the seventh batch of national drug centralized procurement have been released, the drug coverage has been further expanded, and the drug price reduction is more rational. The state's "group purchase" replaces the price with the quantity to squeeze out the moisture in the drug price, bringing real benefits to patients. In the opinion of the interviewed experts, the centralized purchase is to enable the majority of patients to buy good drugs with consistent evaluation at a lower price. However, it is not blindly reducing prices, but to achieve a win-win situation for patients, medical insurance funds, pharmaceutical enterprises and hospitals. In 31 treatment categories, 60 kinds of drugs were successfully purchased, with an average price reduction of 48%. Recently, with the selection results of the seventh batch of national organized centralized drug procurement, the price of "one pill" has once again touched people's hearts. Since 2018, China has carried out seven batches of national drug centralized procurement, covering a total of 294 kinds of drugs. The average drop in drug prices is more than 50%. The first six batches of centralized procurement have saved more than 260 billion yuan in medical expenses. The seventh batch of centralized procurement is expected to save 18.5 billion yuan per year. This time, the national centralized procurement has further expanded the coverage of drugs, and the reduction of drug prices is more rational. At the same time, the mechanism of standby supply enterprises has been introduced to implement the "inter product fuse". It is only one aspect of centralized drug purchase to squeeze water at the price of quantity to "reduce the weight" of drug price and reduce the burden of patients. The price of "one pill" involves the interests of patients, enterprises, hospitals and medical insurance funds. The centralized purchase of drugs is also like a stone thrown into the lake, which continues to stir up ripples. Behind the mild drop, the drop in drug prices directly affects the "money bags" of patients. Every time the national drug "group purchase", the drop figures have attracted much attention. Compared with the average decrease of 53% in the price of the first six batches of national drug centralized purchase, the average decrease of 48% in this centralized purchase is relatively mild. Jiang Changshong, assistant to the president of the National Medical Security Research Institute and director of the price bidding and procurement office, analyzed that, on the one hand, after several rounds of centralized procurement, enterprises have made rational quotations, and the varieties of "floor prices" are less and less, and they are more inclined to obtain reasonable profits and expectations; On the other hand, the inter provincial alliance, the regional alliance and the individual centralized procurement of each province are all in progress. Some varieties of this centralized procurement have been included in the local centralized procurement catalogue. The water content of the drug price has been squeezed once, so there is naturally little room for price reduction. Yao Yu, deputy director of the cultural behavior Laboratory of the Chinese Academy of Social Sciences and professor of the school of economics of the University of the Chinese Academy of Social Sciences, also expressed similar views. "Some drugs selected in centralized purchase may not be produced by our factory, but may be produced by OEM. Therefore, it is also necessary to reserve premium space for potential risks such as rising raw materials and OEM costs." Yao Yu added that in order to avoid the phenomenon of drug supply interruption in centralized procurement, it is necessary to leave sufficient price space for enterprises. In the opinion of the interviewed experts, centralized procurement is to enable the majority of patients to buy good drugs with consistent evaluation at a lower price. However, it is not to reduce the price blindly, but to achieve a win-win situation for patients, medical insurance funds, pharmaceutical enterprises and hospitals. It can be predicted that after several rounds of centralized procurement squeeze out the water with high drug prices, the price reduction of centralized procurement will be weakened in the future,